RBI Strategies & Research conducted a poll in Colorado between March 17 and 19 this year, and the findings of that poll are out. The survey results have given activists the impetus that they need to consider putting a psilocybin ballot measure on the 2022 ballot.
This positive news comes approximately one year after the city of Denver made history as the first U.S. city to decriminalize the possession of “magic mushrooms.” This milestone was reached after the tireless work done by “Decriminalize Denver” paid off.
Now the recent survey conducted by RBI has provided more good news for the advocates because the poll indicated that the people of Colorado support not just expanding what was achieved in Denver to the entire state, but also creating a legal supply chain which would allow trained medical professionals to access psilocybin and use it to treat a host of mental conditions, such as anxiety, PTSD and addiction.
It should be noted that the suggested ballot initiative used in the poll was comprehensive and had provisions beyond simply legalizing psilocybin. For example, the initiative included language that referred to a licensing policy whose scope could go beyond medicinal uses of psilocybin.
Nevertheless, five in ten respondents expressed support for this measure, and nearly three in ten expressed strong support for such reforms.
Furthermore, 54% of the respondents said that they were in support of any measure that would see “certain natural remedies, such as psilocybin” legalized. 52% supported the use of psychedelics to treat patients with any of the ailments on a list of qualifying conditions, such as terminal illnesses.
Kevin Mathews, Decriminalize Denver’s campaign manager, said that it was encouraging that half of the voter population in Colorado supports the decriminalization and regulation of psilocybin mushrooms.
The survey about psilocybin in Colorado isn’t unique in the psychedelics space. Another survey on the same issue was conducted in Washington, D.C., and 51% of the people surveyed expressed support for reforms aimed at decriminalizing plant-based psychedelics.
In the same vein, campaigners in Oregon submitted more than the required number of voter signatures in order to put a psilocybin measure on the November ballot. This group is just awaiting confirmation from the office of the Oregon secretary of state since the signature submission deadline expired yesterday. The confirmation is expected later this month.
The tide seems to be in favor of psilocybin legalization in different parts of the country, and this trend is likely to give industry players like Cybin Corp. added impetus to step up their R&D efforts so that the needs of the population are met as more psychedelic medicines are approved for use.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.